Jean-François Dufour (Jean-Francois Dufour, Jean Francois Dufour)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 26

Top Venues

Gut

Cancers

Nature

Nature reviews. Gastroenterology & hepatology

Insel Gruppe AG

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Insel Gruppe AG Apr 01 2005

Switzerland

Clinic Director UVCM Hepatology / Head Physician Hepatology :: University Clinic for Visceral Surgery and Medicine / Hepatology

Publications

Jean-François Dufour, Vincent Wai-Sun Wong
Non-invasive assessment of MASH resolution. Gut (2024)
Jean-François Dufour, Vincent Wai-Sun Wong
Non-invasive assessment of MASH resolution. Gut 73 (8) (2024)
Jean-François Dufour
A pivotal year for NAFLD and NASH therapeutics. Nature reviews. Endocrinology 20 (2) (2024)
Jean-François Dufour, Vincent Wai-Sun Wong
Non-invasive assessment of MASH resolution. Gut 73 (8) (2024)
Melisa Dirchwolf, Chiara Becchetti, Susanne Stampf, Christa Haldimann, Franz F Immer, Franziska Beyeler, Christian Toso, Philipp Dutkowski, Daniel Candinas, Jean-François Dufour, Vanessa M Banz, null null
The impact of perceived donor liver quality on post-transplant outcome. ANZ journal of surgery (2023)
Jean-François Dufour
A pivotal year for NAFLD and NASH therapeutics. Nature reviews. Endocrinology (2023)
Jean-François Dufour, Thomas Marjot, Chiara Becchetti, Herbert Tilg
COVID-19 and liver disease. Gut 71 (11) (2022)
Chaonan Jin, Eric Felli, Naomi Franziska Lange, Annalisa Berzigotti, Jordi Gracia-Sancho, Jean-François Dufour
Endoplasmic Reticulum and Mitochondria Contacts Correlate with the Presence and Severity of NASH in Humans. International journal of molecular sciences 23 (15) (2022)
Pompilia Radu, Maryam Ebadi, Aldo J Montano-Loza, Jean-François Dufour
What Is the Role of Body Composition Assessment in HCC Management? Cancers 14 (21) (2022)
Yasser Mahrous Fouad, Jean-François Dufour, Ming-Hua Zheng, Steven Bollipo, Hailemichael Desalegn Mekonnen, Henning Grønbaek, Robert G Gish
The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology? Liver international : official journal of the International Association for the Study of the Liver 42 (4) (2022)
Naomi Franziska Lange, Vanessa Graf, Cyrielle Caussy, Jean-François Dufour
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. International journal of molecular sciences 23 (8) (2022)
Jean-François Dufour, Quentin Mark Anstee, Elisabetta Bugianesi, Stephen Harrison, Stephen Caldwell, Valerie Paradis, Herbert Tilg, Vincent Wai-Sun Wong, Shira Zelber-Sagi
Current therapies and new developments in NASH. Gut (2022)
Michael Dudek, Dominik Pfister, Sainitin Donakonda, Pamela Filpe, Annika Schneider, Melanie Laschinger, Daniel Hartmann, Norbert Hüser, Philippa Meiser, Felix Bayerl, Donato Inverso, Jennifer Wigger, Marcial Sebode, Rupert Öllinger, Roland Rad, Silke Hegenbarth, Martina Anton, Adrien Guillot, Andrew P Bowman, Danijela Heide, Florian Müller, Pierluigi Ramadori, Valentina Leone, Cristina Garcia-Caceres, Tim Gruber, Gabriel Seifert, Agnieszka M Kabat, Jan Philipp Mallm, Simon Reider, Maria Effenberger, Susanne Roth, Adrian T Billeter, Beat Müller-Stich, Edward J Pearce, Friedrich Koch-Nolte, Rafael Käser, Herbert Tilg, Robert Thimme, Tobias Boettler, Frank Tacke, Jean-François Dufour, Dirk Haller, Peter J Murray, Ron M A Heeren, Dietmar Zehn, Jan Philipp Böttcher, Mathias F Heikenwälder, Percy A Knolle
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature 592 (7854) (2021)
Marta Correia de Sousa, Nicolas Calo, Cyril Sobolewski, Monika Gjorgjieva, Sophie Clément, Christine Maeder, Dobrochna Dolicka, Margot Fournier, Laurent Vinet, Xavier Montet, Jean-François Dufour, Bostjan Humar, Francesco Negro, Christine Sempoux, Michelangelo Foti
Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. Cancers 13 (19) (2021)
Dominik Pfister, Nicolás Gonzalo Nuñez, Roser Pinyol, Olivier Govaere, Matthias Pinter, Marta Szydlowska, Revant Gupta, Mengjie Qiu, Aleksandra Deczkowska, Assaf Weiner, Florian Müller, Ankit Sinha, Ekaterina Friebel, Thomas Engleitner, Daniela Lenggenhager, Anja Moncsek, Danijela Heide, Kristin Stirm, Jan Kosla, Eleni Kotsiliti, Valentina Leone, Michael Dudek, Suhail Yousuf, Donato Inverso, Indrabahadur Singh, Ana Teijeiro, Florian Castet, Carla Montironi, Philipp K Haber, Dina Tiniakos, Pierre Bedossa, Simon Cockell, Ramy Younes, Michele Vacca, Fabio Marra, Jörn M Schattenberg, Michael E D Allison, Elisabetta Bugianesi, Vlad Ratziu, Tiziana Pressiani, Antonio D'Alessio, Nicola Personeni, Lorenza Rimassa, Ann K Daly, Bernhard Scheiner, Katharina Pomej, Martha M Kirstein, Arndt Vogel, Markus Peck-Radosavljevic, Florian Hucke, Fabian Finkelmeier, Oliver Waidmann, Jörg Trojan, Kornelius Schulze, Henning Wege, Sandra Koch, Arndt Weinmann, Marco Bueter, Fabian Rössler, Alexander Siebenhüner, Sara De Dosso, Jan Philipp Mallm, Viktor Umansky, Manfred Jugold, Tom Luedde, Andrea Schietinger, Peter Schirmacher, Brinda Emu, Hellmut G Augustin, Adrian Billeter, Beat Müller-Stich, Hiroto Kikuchi, Dan G Duda, Fabian Kütting, Dirk-Thomas Waldschmidt, Matthias Philip Ebert, Nuh Rahbari, Henrik E Mei, Axel Ronald Schulz, Jane A McKeating, Nisar Malek, Stephan Spahn, Michael Bitzer, Marina Ruiz de Galarreta, Amaia Lujambio, Jean-François Dufour, Thomas U Marron, Ahmed Kaseb, Masatoshi Kudo, Yi-Hsiang Huang, Nabil Djouder, Katharina Wolter, Lars Zender, Parice N Marche, Thomas Decaens, David James Pinato, Roland Rad, Joachim C Mertens, Achim Weber, Kristian Unger, Rüdiger Klein, Susanne Roth, Zuzana Macek Jilkova, Manfred Claassen, Quentin M Anstee, Bjørt K Kragesteen, Percy A Knolle, Burkhard Becher, Josep M Llovet, Mathias F Heikenwälder
NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592 (7854) (2021)
Víctor Sapena, Marco Enea, Ferràn Torres, Ciro Celsa, Jose Ríos, Giacomo Emanuele Maria Rizzo, Pierre Nahon, Zoe Mariño, Ryosuke Tateishi, Tatsuya Minami, Angelo Sangiovanni, Xavier Forns, Hidenori Toyoda, Stefano Brillanti, Fabio Conti, Elisabetta Degasperi, Ming-Lung Yu, Pei-Chien Tsai, Kévin Jean, Mohamed El Kassas, Hend Ibrahim Shousha, Ashraf Omar, Claudio Zavaglia, Hiroko Nagata, Mina Nakagawa, Yasuhiro Asahina, Amit G Singal, Caitlin C Murphy, Mohamed Ahmed Samy Kohla, Chiara Masetti, Jean-François Dufour, Nicolás Merchante, Luisa Cavalletto, Liliana Lc Chemello, Stanislas Pol, Javier Crespo, Jose Luis Calleja, Rosanna Villani, Gaetano Serviddio, Alberto Zanetto, Sarah Shalaby, Francesco Paolo Russo, Rob Bielen, Franco Trevisani, Calogero Cammà, Jordi Bruix, Giuseppe Cabibbo, Maria Reig
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut (2021)
Mojgan Masoodi, Francesco Rubino, Tuulia Hyötyläinen, Enara Arretxe, Cristina Alonso, Melania Gaggini, Julia Brosnan, Quentin Mark Anstee, Oscar Millet, Pablo Ortiz, Jose M Mato, Jean-François Dufour, Matej Orešič
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature reviews. Gastroenterology & hepatology 18 (12) (2021)
Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, Misti Vanette McCain, Robyn Watson, Yang Lin Liu, Nikki McStraw, Moustafa Fathy, Michael Atef Fawzy, Marco Y W Zaki, Ann K Daly, João P Maurício, Alastair D Burt, Beate Haugk, Heather J Cordell, Cristiana Bianco, Jean-François Dufour, Luca Vittorio Valenti, Quentin Mark Anstee, Helen L Reeves
A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? Cancers 13 (6) (2021)
Iuliana Pompilia Radu, Jean-François Dufour
Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 69 (8) (2020)
Sven M Francque, Gyongyi Szabo, Manal F Abdelmalek, Christopher D Byrne, Kenneth Cusi, Jean-François Dufour, Michael Roden, Frank Sacks, Frank Tacke
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nature reviews. Gastroenterology & hepatology 18 (1) (2020)
Jean-François Dufour, Cyrielle Caussy, Rohit Loomba
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 69 (10) (2020)
Cyril Sobolewski, Daniel Abegg, Flavien Berthou, Dobrochna Dolicka, Nicolas Calo, Christine Sempoux, Margot Fournier, Christine Maeder, Anne-Sophie Ay, Pierre-Alain Clavien, Bostjan Humar, Jean-François Dufour, Alexander Adibekian, Michelangelo Foti
S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Gut 69 (10) (2020)
Stephan Spahn, Daniel Roessler, Radu Pompilia, Gisela Gabernet, Beryl Primrose Gladstone, Marius Horger, Saskia Biskup, Magdalena Feldhahn, Sven Nahnsen, Franz J Hilke, Bernhard Scheiner, Jean-François Dufour, Enrico N De Toni, Matthias Pinter, Nisar P Malek, Michael Bitzer
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers 12 (12) (2020)
Chiara Becchetti, Marco Fabrizio Zambelli, Luisa Pasulo, Maria Francesca Donato, Federica Invernizzi, Olivier Detry, Géraldine Dahlqvist, Olga Ciccarelli, Maria Cristina Morelli, Montserrat Fraga, Gianluca Svegliati-Baroni, Hans van Vlierberghe, Minneke J Coenraad, Mario Cristobal Romero, Andrea de Gottardi, Pierluigi Toniutto, Luca Del Prete, Claudia Abbati, Didier Samuel, Jacques Pirenne, Frederik Nevens, Jean-François Dufour, null null
COVID-19 in an international European liver transplant recipient cohort. Gut 69 (10) (2020)
Richard D Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong-Won Park, Su Pin Choo, Antoine Hollebecque, Max W Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X Zhu, Jung-Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L Chan, Sandrine Faivre, Lynn G Feun, Chia-Jui Yen, Jean-François Dufour, Daniel H Palmer, Josep M Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt-Kittler, Klaus P Hoeflich, Hongliang Shi, Beni B Wolf, Yoon-Koo Kang
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery 9 (12) (2019)
Matias A Avila, Jean-François Dufour, Alexander L Gerbes, Fabien Zoulim, Ramon Bataller, Patrizia Burra, Helena Cortez-Pinto, Bin Gao, Ian Gilmore, Philippe Mathurin, Christophe Moreno, Vladimir Poznyak, Bernd Schnabl, Gyongyi Szabo, Maja Thiele, Mark R Thursz
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut 69 (4) (2019)

Jean-François Dufour.css-eqlu8i{font-size:small;padding-left:4px;} (Jean-Francois Dufour, Jean Francois Dufour)

Publication Activity (10 Years)

Top Topics

Top Venues

Jean-François Dufour (Jean-Francois Dufour, Jean Francois Dufour)